AdvanSource Biomaterials Corpration (ASNB) & Cryolife (CRY) Critical Review
AdvanSource Biomaterials Corpration (OTCMKTS:ASNB) and Cryolife (NYSE:CRY) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, analyst recommendations, dividends, earnings and profitability.
Valuation & Earnings
This table compares AdvanSource Biomaterials Corpration and Cryolife’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|AdvanSource Biomaterials Corpration||$2.92 million||0.44||-$200,000.00||N/A||N/A|
|Cryolife||$189.70 million||5.31||$3.70 million||$0.40||68.10|
This table compares AdvanSource Biomaterials Corpration and Cryolife’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|AdvanSource Biomaterials Corpration||5.06%||-24.67%||5.28%|
Institutional and Insider Ownership
71.1% of Cryolife shares are held by institutional investors. 7.8% of AdvanSource Biomaterials Corpration shares are held by insiders. Comparatively, 4.0% of Cryolife shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
This is a summary of current ratings and recommmendations for AdvanSource Biomaterials Corpration and Cryolife, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|AdvanSource Biomaterials Corpration||0||0||0||0||N/A|
Cryolife has a consensus price target of $34.00, indicating a potential upside of 24.82%. Given Cryolife’s higher possible upside, analysts plainly believe Cryolife is more favorable than AdvanSource Biomaterials Corpration.
Volatility & Risk
AdvanSource Biomaterials Corpration has a beta of -3.74, suggesting that its stock price is 474% less volatile than the S&P 500. Comparatively, Cryolife has a beta of 0.57, suggesting that its stock price is 43% less volatile than the S&P 500.
Cryolife beats AdvanSource Biomaterials Corpration on 9 of the 12 factors compared between the two stocks.
AdvanSource Biomaterials Corpration Company Profile
AdvanSource Biomaterials Corporation develops polymer materials for use in the design and development of medical devices used for treating a range of anatomical sites and disease states. It offers polymers under the ChronoFilm, ChronoFlex, ChronoThane, ChronoPrene, ChronoSil, HydroThane, HydroMed, and PolyBlend trade names. The company also manufactures specialty hydrophilic polyurethanes. It sells its products directly to the customers in the United States. The company was formerly known as CardioTech International, Inc. and changed its name to AdvanSource Biomaterials Corporation in October 2008. AdvanSource Biomaterials Corporation was founded in 1993 and is headquartered in Wilmington, Massachusetts.
Cryolife Company Profile
CryoLife, Inc., together with its subsidiaries, manufactures, processes, and distributes medical devices and implantable human tissues for use in cardiac and vascular surgeries worldwide. The company operates in two segments, Medical Devices and Preservation Services. It offers BioGlue, an agent for cross-linking proteins for cardiac, vascular, pulmonary, and general surgical applications; On-X mechanical heart valves for aortic and mitral indications; cardiac preservation services; PhotoFix, a bovine pericardial patch for use in cardiac and vascular repairing activities; and PerClot, an absorbable powdered hemostat for use in surgical procedures, including cardiac, vascular, orthopedic, neurological, gynecological, ENT, and trauma surgeries. The company also provides cardiac laser therapy products, which include laser consoles, related service and maintenance, and single-use, as well as fiber-optic hand-pieces for the treatment of coronary artery disease in patients with severe angina. In addition, it distributes E-vita OPEN PLUS, a hybrid stent graft systems for the surgical and endovascular treatment; E-xtra DESIGN ENGINEERING products for the treatment of aortic vascular diseases; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac, a stent graft used to treat aneurysmal iliac arteries, as well as aneurysmal iliac side branches; E-vita THORACIC 3G is a stent graft system for the endovascular treatment of thoracic aortic aneurysms; and E-tegra, an abdominal aortic aneurysms stent graft system for the endovascular treatment. Further, the company offers vascular preservation services; and synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures. The company serves physicians, hospitals, and other healthcare industries, as well as cardiac, vascular, thoracic, and general surgeons. CryoLife, Inc. was founded in 1984 and is headquartered in Kennesaw, Georgia.
Receive News & Ratings for AdvanSource Biomaterials Corpration Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AdvanSource Biomaterials Corpration and related companies with MarketBeat.com's FREE daily email newsletter.